Press Releases Recent Releases September 6, 2022 Athira Pharma Provides Update on Plans for Ongoing LIFT-AD Clinical Study of Fosgonimeton in Mild-to-Moderate Alzheimer’s Patients August 15, 2022 Athira Pharma Reports Second Quarter 2022 Financial Results and Recent Clinical and Corporate Updates August 3, 2022 Athira Pharma Presents Data from ACT-AD Phase 2 Proof-of-Concept Clinical Study of Fosgonimeton in Mild-to-Moderate Alzheimer’s Patients at the Alzheimer's Association International Conference 2022 Press Releases Year None2022202120202019 April 11, 2019 M3 Biotechnology Announces Name Change to Athira Pharma, Inc. Pagination First page « first Previous page ‹ previous Page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Current page 9 Displaying 81 - 81 of 81
Recent Releases September 6, 2022 Athira Pharma Provides Update on Plans for Ongoing LIFT-AD Clinical Study of Fosgonimeton in Mild-to-Moderate Alzheimer’s Patients August 15, 2022 Athira Pharma Reports Second Quarter 2022 Financial Results and Recent Clinical and Corporate Updates August 3, 2022 Athira Pharma Presents Data from ACT-AD Phase 2 Proof-of-Concept Clinical Study of Fosgonimeton in Mild-to-Moderate Alzheimer’s Patients at the Alzheimer's Association International Conference 2022 Press Releases Year None2022202120202019 April 11, 2019 M3 Biotechnology Announces Name Change to Athira Pharma, Inc. Pagination First page « first Previous page ‹ previous Page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Current page 9 Displaying 81 - 81 of 81
